|BioTime Expands & Advances Ophthalmology Portfolio|
“OpRegen is making great progress in the clinic,” said
A poster demonstrating similarities between normal human retinal tissue and laboratory grown 3D retinal tissue derived using BioTime’s proprietary methodology with pluripotent cells (hPSC) was presented during ISSCR. The study compared normal human retinal cells with the BioTime’s proprietary hPSC-derived 3D retinal tissue for the potential use in helping to restore vision for blind people with advanced stages of retinal degeneration. The results presented demonstrated high correlation in gene expression profiles, between the various cellular components of normal human retinal tissue and the hPSC-derived tissue, including retinal pigment epithelium, retinal progenitor, photoreceptor, amacrine and ganglion cells.
In addition, the most recent data from the ongoing Phase I/II clinical
trial of the lead product, OpRegen®, for the treatment of dry
age-related macular degeneration was presented during the conference.
The Phase I/IIa dose-escalation study evaluating the safety and efficacy
of three different dose regimens of the company’s investigational
product, OpRegen®. OpRegen® has received Fast Track designation from the
TVST Journal Publication
“These studies continue to leverage and expand our proprietary approaches utilizing hPSCs for a broad range of ocular diseases associated with cellular and tissue degeneration that other therapeutic approaches can’t address effectively,” said Oscar Cuzzani, M.D., Ph.D., BioTime’s Vice President of Clinical Development. “As ophthalmology remains among BioTime’s core areas of focus, we are uniquely positioned with our broad expertise, capabilities and IP portfolio in regenerative ophthalmology, creating a stronger pipeline to address problems of degenerative diseases of the eye.”
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for
To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn,